131 Dartmouth Street
3rd Floor
Boston, MA 02116
United States
650 503 9095
https://www.adicetbio.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 143
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Aya Jakobovits Ph.D. | Founder & Independent Director | 45k | S.O. | 1955 |
Mr. Brian Nicholas Harvey | Chief Financial Officer | 594,94k | S.O. | 1961 |
Dr. Donald Healey Ph.D. | Chief Technology Officer | 606,34k | S.O. | 1962 |
Dr. Blake Aftab Ph.D. | Senior VP & Chief Scientific Officer | 675,04k | S.O. | 1981 |
Ms. Amy Locke | Chief Human Resource Officer | S.O. | S.O. | S.O. |
Dr. Francesco Galimi M.D., Ph.D. | Chief Medical Officer & Senior VP | 680,37k | S.O. | 1968 |
Dr. Nancy L. Boman M.D., Ph.D. | Senior VP & Chief Regulatory Officer | S.O. | S.O. | S.O. |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
L’ISS Governance QualityScore de Adicet Bio, Inc. en date du 1 mai 2024 est 9. Les scores principaux sont Audit : 6; Société : 9; Droits des actionnaires : 8; Compensation : 9.